We got a glimpse of real journalism wriggling out of the mainstream this week…
It was pretty refreshing. It’s been a while.
We wish we could say the same about the story.
It made the cover of Newsweek. Here’s the picture…
You might’ve heard about this story. The most shocking part of it all, as you’ll see, is how routine it is in the world of “medicine.”
The article begins with the story of one 14-year-old Japanese girl.
She had been experiencing paranoid delusions.
You know the kind…
She thought someone was watching her. She thought someone was in the house. She felt like someone was watching her. And then, later, over a meal, she was convinced her food was poisoned.
A couple days later, she turned suicidal.
Odd thing is…
She had no history of mental illness.
But it hadn’t just sprung up out of nowhere…
The symptoms began when she started taking Tamiflu, the anti-influenza drug (also known as oseltamivir). The same drug that governments the world over have spent billions stockpiling (the U.S. alone spent $1.5 billion on a huge supply) since it received the FDA’s stamp of approval in 1999.
The Japanese teen lived. Others that took the drug weren’t so lucky.
At least 70 people have died from Tamiflu, many by suicide. One 14-year-old jumped off a balcony… one 17-year-old ran in front of a truck… a South Korean girl developed a temporary bout of bipolar disorder… and an 8-year-old displayed unusual behavior like growling and not responding to his name, among others.
Sure, this doesn’t happen to everyone.
“Tens of millions of people have taken Tamiflu without incident,” Newsweek’s Ben Wolford admits, “and you are far more likely to die from the flu than you are to have a dangerous reaction to the drug.”
So what’s the fuss?
Well, according to the Cochrane Collaboration, one of the most meticulous scrutinizers of health science data, here’s the real problem: Tamiflu didn’t do what it was supposed to.
Therefore, it’s potentially harmful and probably ineffective. Not a great combination for a drug that’s being counted on all around the globe for the future safety of humanity.
Cochrane Collaboration, if you don’t know, is considered the gold standard in medicine. It’s a global not-for-profit organization of 14,000 academics that do their own independent research. Just like yours truly, Cochrane isn’t tethered to any commercial purse strings or any other conflicts of interest.
They let the research lead the way — just how it should be.
Unfortunately, that’s not the way Big Pharma likes to operate. More on that in a moment.
Tamiflu was thought by its creator, Roche Pharmaceuticals, to work by trapping the virus inside the cell.
Normally, a virus will copy itself in the nucleus of a cell and burst out of the cell membrane once its strong enough in order to infect more cells. Tamiflu was supposed to stop that “bursting out” from happening.
“That was the theory,” Wolford says. “Roche paid >> READ MORE <<
SOURCE ARTICLE: : http://lfb.org/exposed-fdas-pants-quick-look/